ArticleClinical and experimental nephrology2026
Effects of individual sodium-glucose cotransporter-2 inhibitors on all-cause mortality in patients with diabetic kidney disease.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEvidence on the drug effect of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on mortality in patients with diabetic kidney disease (DKD) remains limited. We analyzed patients with DKD newly prescribed SGLT2is using large-scale Asian real-world data.
methodsWe utilized commercially available databases provided by DeSC Healthcare, Inc., between 2014 and 2023. All-cause mortality was compared across five pairs of new users of SGLT2is-canagliflozin, empagliflozin, ipragliflozin, luseogliflozin, or tofogliflozin-each versus dapagliflozin, using a target trial emulation framework with propensity score matching.
resultsAmong 12,308 patients with DKD, 1,553 new users of canagliflozin, 2,948 of empagliflozin, 1,672 of ipragliflozin, 931 of luseogliflozin, and 955 of tofogliflozin were matched 1:1 with corresponding new users of dapagliflozin. The mean age of participants ranged from 72.2 to 75.4 years, and 67.4-72.2% were men. During a median follow-up period of 1.12-1.96 years, the incidence of all-cause mortality among new users of SGLT2 inhibitors ranged from 32.3 to 46.2 for dapagliflozin, and was 28.8 for canagliflozin, 38.8 for empagliflozin, 33.4 for ipragliflozin, 33.8 for luseogliflozin, and 25.7 for tofogliflozin, per 1,000 person-years. Both the cumulative incidence and hazard ratios for all-cause mortality were comparable among new users of each SGLT2i compared with dapagliflozin (all log-rank P > 0.05; 95% CIs included 1).
conclusionsComparable effects of SGLT2is on all-cause mortality risk were observed in patients with DKD using the Asian real-world data. This apparent class effect on all-cause mortality suggests that different agents may confer comparable short-term mortality benefits when selected according to patient characteristics.
Indexed as
Identifiers
41963737What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.